{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-235830","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2021-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.092444+00:00","generated_at":"2026-06-29T22:29:50.158233+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Fate Therapeutics appoints Yuan Xu, Ph.D. to Board of Directors","bullets":["Board expanded from 9 to 10 directors; Yuan Xu appointed as Class II director effective August 3, 2021.","Dr. Xu granted option to purchase 7,501 shares and RSUs for 4,744 shares, vesting over 3 years.","Dr. Xu previously CEO of Legend Biotech, led cilta-cel development and partnership with Janssen.","Over 25 years biopharma experience including senior roles at Merck, Gilead, and Novartis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-235830","json":"https://secwatch.observer/filing/0001193125-21-235830.json","markdown":"https://secwatch.observer/filing/0001193125-21-235830.md","text":"https://secwatch.observer/filing/0001193125-21-235830.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312521235830/0001193125-21-235830-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312521235830/d213764d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:29:50.158233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6cc440fe13","claim":"Yuan Xu was appointed as Class II director at FATE THERAPEUTICS INC.","evidence_excerpt":"On August 3, 2021, the Board appointed Yuan Xu, Ph.D. to the Board as a Class II director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312521235830/0001193125-21-235830-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}